News
BBIO
24.33
-2.80%
-0.70
Analysts Anticipate ESML Will Reach $45
NASDAQ · 3d ago
Weekly Report: what happened at BBIO last week (0415-0419)?
Weekly Report · 3d ago
First Week of January 2026 Options Trading For BridgeBio Pharma (BBIO)
NASDAQ · 6d ago
Relative Strength Alert For BridgeBio Pharma
NASDAQ · 04/15 20:57
Weekly Report: what happened at BBIO last week (0408-0412)?
Weekly Report · 04/15 09:09
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. Is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers. The company's board of directors approved equity grants to 19 new employees in restricted stock units for an aggregate of 93,088 shares of the Company’s common stock.
Barchart · 04/10 06:30
BRIEF-UK's MHRA Says Fosdenopterin Approved To Treat Adult Patients With Molybdenum Cofactor Deficiency (MoCD) Type A
UK's MHRA Says Fosdenopterin Approved To Treat Adult Patients With Molybdenum Cofactor Deficiency (MoCD) Type A. NEW MARKETING AUTHORISATION granted to TMC PHARMA LTD in 2024. UK's MHra: FOSDENOPTERIN approved to treat adults with MoCD type A.
Reuters · 04/09 17:06
UK'S MHRA: FOSDENOPTERIN (NULIBRY) NEW MARKETING AUTHORISATION WAS GRANTED ON 9 APRIL 2024 TO TMC PHARMA LTD
Reuters · 04/09 15:26
Buy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial Outcomes
TipRanks · 04/08 09:46
Weekly Report: what happened at BBIO last week (0401-0405)?
Weekly Report · 04/08 09:09
Reported Sunday, BridgeBio Pharma Presented Results From The Exploratory Cardiac Magnetic Resonance Imaging Substudy Of ATTRibute-CM, Its Phase 3 trial Of Acoramidis In ATTR-CM
BridgeBio says treatment with acoramidis may enable cardiac remodeling and functional recovery in patients with ATTR-CM. The company's New Drug Application has been accepted by the U.S. FDA and is expected to be approved in 2025. The study shows potential cardiac structural and functional improvement.
Benzinga · 04/08 06:50
Weekly Report: what happened at BBIO last week (0325-0329)?
Weekly Report · 04/01 09:09
TipRanks ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
TipRanks · 03/27 10:25
Weekly Report: what happened at BBIO last week (0318-0322)?
Weekly Report · 03/25 09:09
Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments
Mizuho Securities has maintained a Buy rating on BridgeBio Pharma (BBIO) with a price target of $53.00. Salim Syed has highlighted the introduction of a new tafamidis tablet formulation in Phase 1 trials as a key factor. The company is developing a drug to treat the ATTR-CM market.
TipRanks · 03/25 01:47
BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident
BridgeBio Pharma has submitted a New Drug Application for acoramidis, a potential treatment for transthyretin amyloid cardiomyopathy. The company raised $300m in one of the largest biotech IPOs of the year. The drug has a potential to generate peak revenues of $1.8bn for the company. BridgeBio Pharma's stock reached highs of $70 per share in March 2021. The company is developing a drug for the $15bn ATTR market.
Seeking Alpha · 03/22 10:49
Stock Indexes Rally to Record Highs on a Resilient US Economy
S&P 500, Dow Jones Industrials, and Nasdaq 100 post new all-time highs on Thursday. Stocks rallied on the outlook for Fed rate cuts later this year. The Euro Stoxx 50 climbs to a 23-year high and closes up +1.04%. Overseas stock markets on Thursday settled mixed. June T-notes turn lower on stronger-than-expected US economic reports, hawkish factors.
Barchart · 03/21 15:32
BridgeBio Pharma Is Maintained at Overweight by JP Morgan
Dow Jones · 03/20 10:38
BridgeBio Pharma Price Target Raised to $45.00/Share From $35.00 by JP Morgan
Dow Jones · 03/20 10:38
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $45
Benzinga · 03/20 10:28
More
Webull provides a variety of real-time BBIO stock news. You can receive the latest news about Bridgebio Pharma through multiple platforms. This information may help you make smarter investment decisions.
About BBIO
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.